Evidence map›Paper›PMID 15845506›Full record

Trial reportInfection and immunity2005

Efficient Ex vivo stimulation of Mycobacterium tuberculosis-specific T cells by genetically detoxified Bordetella pertussis adenylate cyclase antigen toxoids.

Katalin A Wilkinson, Marcela Simsova, Elisabeth Schölvinck, Peter Sebo, Claude Leclerc, H Martin Vordermeier, Stuart J Dickson, Jillian R Brown, Robert N Davidson, Geoffrey Pasvol and 2 more

Open access · greenAbstract readClinical Trial
In one paragraph

Trial report in Infection and immunity, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Bioengineering ofToxins · 2018
    Review
  3. General and molecular microbiology and microbial genetics in the IM CAS.Journal of industrial microbiology & biotechnology · 2010
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Katalin A WilkinsonWellcome Trust Center for Research in Clinical Tropical Medicine, Imperial College London, Wright Fleming Institute, Norfolk Place, London W2 1PG, United Kingdom. r.j.wilkinson@imperial.ac.uk
Marcela Simsova
Elisabeth Schölvinck
Peter Sebo
Claude Leclerc
H Martin Vordermeier
Stuart J Dickson
Jillian R Brown
Robert N Davidson
Geoffrey Pasvol
Michael Levin
Robert J Wilkinson
Wellcome Trust · GBNorthwick Park Hospital · GBCzech Academy of Sciences · CZImperial College London · GBInstitut Pasteur · FR

Funding

Medical Research Council MC_U117588499
6 · The paper itself

Abstract

Mycobacterium tuberculosis is a significant threat to global health. Mycobacterium bovis BCG vaccine provides only partial protection, and the skin test reagent used to aid diagnosis of both active and latent tuberculosis, purified protein derivative (PPD), lacks specificity and sensitivity. The use of genetically detoxified Bordetella pertussis adenylate cyclase toxin (CyaA) as a delivery system for two immunodominant proteins of M. tuberculosis that are of greater specificity than PPD, early-secreted antigenic target 6-kDa protein (ESAT-6) and culture filtrate protein 10 (CFP-10), was therefore investigated. CyaA toxoids incorporating these antigens were able to restimulate T cells from more than 91% tuberculosis patients and healthy sensitized donors. Delivery of antigen by CyaA decreased by 10-fold the amount of ESAT-6 and CFP-10 required to restimulate T cells, and in low responders, the overall frequency of gamma interferon-producing cells detected by enzyme-linked immunospot assay was increased (P < 0.01 for both antigens). Delivery of ESAT-6 and CFP-10 by CyaA enabled the detection of both CD4(+) and CD8(+) T cells: these responses could be blocked by inhibition of major histocompatibility complex class II or class I, respectively. Covalent linkage of antigen to the CyaA vector was required for enhancement to occur, as a mixture of mock CyaA toxoid plus recombinant ESAT-6 did not lead to enhancement. In a simplified whole-blood model to detect tuberculosis infection, the frequency of positive responses to CFP-10 was increased by CyaA delivery, a potentially important attribute that could facilitate the identification of latent infection.

Indexed as

Drug Delivery SystemsAdenylyl CyclasesAdultAntigens, BacterialBacterial ProteinsBordetella pertussisDose-Response Relationship, ImmunologicFemaleHumansImmunodominant EpitopesInterferon-gammaLymphocyte ActivationMaleMycobacterium tuberculosisRecombinant Fusion ProteinsT-LymphocytesAdenylyl CyclasesAntigens, BacterialBacterial ProteinsCFP-10 protein, Mycobacterium tuberculosisESAT-6 protein, Mycobacterium tuberculosisImmunodominant EpitopesInterferon-gammaRecombinant Fusion ProteinsTuberculosis Vaccines

Identifiers

PMID15845506
PMCPMC1087377
OpenAlexW2144128004

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.